Orion Corporation Announces Conversion of A Shares to B Shares
Orion Corporation Announces Conversion of A Shares to B Shares
Orion Corporation has successfully converted 141,959 A shares into B shares. This operation follows the stipulations set out in the Articles of Association and has been officially entered into the Trade Register. This change signifies a strategic movement within the company's share structure.
Details of the Share Conversion
The conversion process reflects the ongoing adjustments in Orion Corporation's share distribution. After this conversion, the total number of outstanding shares now stands at 141,134,278. The new balance comprises 32,308,783 A shares and a hefty 108,825,495 B shares. As a result of this realignment, the voting shares available have increased to a total of 755,001,155 votes.
Leadership Insights
Leading the charge in Orion Corporation’s strategic movements are its key executives, including Liisa Hurme, the President and CEO, who plays a pivotal role in guiding the company forward. Additionally, Mikko Kemppainen as General Counsel aids in ensuring that all corporate actions remain compliant with legal standards. Their leadership supports the foundation of trust that extends to shareholders and the broader market.
Contact Information for Inquiries
For any inquiries regarding this share conversion or other investor-related questions, Tuukka Hirvonen, the Head of Investor Relations, is available at +358 10 426 2721. He provides insights into Orion's strategic decisions and company policies.
About Orion Corporation
As a Nordic pharmaceutical giant, Orion Corporation has been a cornerstone of health and well-being for over a century. The company's dedication to developing, manufacturing, and marketing both human and veterinary pharmaceuticals sets it apart in the industry. Orion's portfolio includes an extensive range of proprietary and generic medications, alongside consumer health products. A major focus of their R&D efforts lies in oncology and pain management, addressing critical health challenges faced globally.
In the recent fiscal year, Orion reported net sales of EUR 1,542 million, underscoring its position as a trusted member of the pharmaceutical community. With around 3,700 professionals committed to enhancing global health outcomes, Orion is firmly established on the Nasdaq Helsinki, where both its A and B shares are listed.
Frequently Asked Questions
What shares did Orion Corporation convert?
Orion Corporation converted 141,959 A shares into B shares as part of their corporate structure adjustment.
How many total shares does Orion Corporation have now?
The total number of shares in Orion Corporation is now 141,134,278 after the recent conversion.
Who is the CEO of Orion Corporation?
Liisa Hurme serves as the President and CEO of Orion Corporation, leading major corporate initiatives.
What is the primary focus of Orion's pharmaceutical R&D?
Orion's R&D primarily focuses on oncology and pain management therapies, developing treatments for significant health issues.
Where can I find more information about Orion Corporation?
For additional details about Orion Corporation, you can visit their official website at http://www.orionpharma.com.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.